Maze Therapeutics (NASDAQ:MAZE) Price Target Raised to $58.00 at JPMorgan Chase & Co.

Maze Therapeutics (NASDAQ:MAZE) had its price objective raised by JPMorgan Chase & Co. from $52.00 to $58.00 in a report issued on Tuesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other research analysts have also issued reports about the stock. HC Wainwright lifted their price target on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Lifesci Capital upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Wedbush raised their target price on shares of Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a report on Monday, March 16th. Mizuho upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. Finally, BTIG Research reaffirmed a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday, March 25th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Maze Therapeutics currently has an average rating of “Buy” and a consensus price target of $66.44.

Maze Therapeutics Trading Up 2.9%

MAZE stock opened at $29.85 on Tuesday. The stock’s 50 day simple moving average is $45.08 and its 200 day simple moving average is $38.00. Maze Therapeutics has a 12-month low of $6.71 and a 12-month high of $53.65. The firm has a market cap of $1.48 billion, a P/E ratio of -9.24 and a beta of 4.47.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08.

Insider Transactions at Maze Therapeutics

In other Maze Therapeutics news, insider Atul Dandekar sold 7,500 shares of the business’s stock in a transaction dated Thursday, January 29th. The shares were sold at an average price of $44.27, for a total transaction of $332,025.00. Following the completion of the transaction, the insider directly owned 10,503 shares of the company’s stock, valued at $464,967.81. The trade was a 41.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Amy Bachrodt sold 5,000 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $46.04, for a total transaction of $230,200.00. Following the completion of the transaction, the senior vice president owned 12,965 shares of the company’s stock, valued at approximately $596,908.60. This trade represents a 27.83% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 112,500 shares of company stock worth $5,132,812.

Hedge Funds Weigh In On Maze Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in MAZE. Royal Bank of Canada increased its position in Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after acquiring an additional 363 shares during the period. Ameritas Investment Partners Inc. grew its stake in shares of Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares in the last quarter. California State Teachers Retirement System grew its stake in shares of Maze Therapeutics by 138.0% in the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after purchasing an additional 766 shares in the last quarter. Police & Firemen s Retirement System of New Jersey increased its holdings in shares of Maze Therapeutics by 18.5% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock valued at $247,000 after purchasing an additional 931 shares during the period. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Maze Therapeutics during the fourth quarter valued at about $39,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.